Ann-Kathrin Eisfeld | Molecular Profiles | Best Researcher Award Published on 20/09/202520/09/2025 by Cell Biologist Prof. Dr. Ann-Kathrin Eisfeld | Molecular Profiles | Best Researcher Award The Ohio State University | United States Dr. Ann-Kathrin Eisfeld is an internationally recognized physician-scientist and Associate Professor with Tenure in the Division of Hematology at The Ohio State University, where she also serves as Director of the Clara D. Bloomfield Center for Leukemia Outcomes Research. Her research focuses on the molecular and genetic underpinnings of acute myeloid leukemia (AML), with a particular emphasis on translational applications that improve patient outcomes. Dr. Eisfeld has published extensively in high-impact journals such as Nature, Leukemia, Blood, and Cell Stem Cell, contributing significantly to our understanding of leukemia biology, clonal evolution, and treatment resistance. she has authored over 100 peer-reviewed scientific publications, with an h-index of 38, more than 6,500 citations, and has led or co-led multiple collaborative studies within national consortia such as the Alliance for Clinical Trials in Oncology. Her work has identified critical biomarkers and therapeutic targets in AML, including insights into TP53 mutations, FLT3 alterations, and resistance mechanisms to venetoclax. Recognized for her integration of clinical insight with cutting-edge genomics, Dr. Eisfeld is a leading voice in precision oncology and leukemia research, shaping the future of individualized treatment strategies through both clinical innovation and scientific discovery. Profile: Scopus Featured Publications: “Highly elevated serum hepcidin in patients with acute myeloid leukemia prior to and after allogeneic hematopoietic cell transplantation: Does this protect from excessive parenchymal iron loading?” “Heritable polymorphism predisposes to high BAALC expression in acute myeloid leukemia” “miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia” “Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia” “Kinetics of iron removal by phlebotomy in patients with iron overload after allogeneic hematopoietic cell transplantation” “inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations” “Clinical Role of microRNAs in Cytogenetically Normal Acute Myeloid Leukemia: miR-155 Upregulation Independently Identifies High-Risk Patients” “In rare acute myeloid leukemia patients harboring both RUNX1 and NPM1 mutations, RUNX1 mutations are unusual in structure and present in the germline” “A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia”
Dr. Ann-Kathrin Eisfeld is an internationally recognized physician-scientist and Associate Professor with Tenure in the Division of Hematology at The Ohio State University, where she also serves as Director of the Clara D. Bloomfield Center for Leukemia Outcomes Research. Her research focuses on the molecular and genetic underpinnings of acute myeloid leukemia (AML), with a particular emphasis on translational applications that improve patient outcomes. Dr. Eisfeld has published extensively in high-impact journals such as Nature, Leukemia, Blood, and Cell Stem Cell, contributing significantly to our understanding of leukemia biology, clonal evolution, and treatment resistance. she has authored over 100 peer-reviewed scientific publications, with an h-index of 38, more than 6,500 citations, and has led or co-led multiple collaborative studies within national consortia such as the Alliance for Clinical Trials in Oncology. Her work has identified critical biomarkers and therapeutic targets in AML, including insights into TP53 mutations, FLT3 alterations, and resistance mechanisms to venetoclax. Recognized for her integration of clinical insight with cutting-edge genomics, Dr. Eisfeld is a leading voice in precision oncology and leukemia research, shaping the future of individualized treatment strategies through both clinical innovation and scientific discovery. Profile: Scopus Featured Publications: “Highly elevated serum hepcidin in patients with acute myeloid leukemia prior to and after allogeneic hematopoietic cell transplantation: Does this protect from excessive parenchymal iron loading?” “Heritable polymorphism predisposes to high BAALC expression in acute myeloid leukemia” “miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia” “Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia” “Kinetics of iron removal by phlebotomy in patients with iron overload after allogeneic hematopoietic cell transplantation” “inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations” “Clinical Role of microRNAs in Cytogenetically Normal Acute Myeloid Leukemia: miR-155 Upregulation Independently Identifies High-Risk Patients” “In rare acute myeloid leukemia patients harboring both RUNX1 and NPM1 mutations, RUNX1 mutations are unusual in structure and present in the germline” “A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia”